Condition: DIPG Brain Tumor · Diffuse Intrinsic Pontine Glioma · Sponsor: Chulalongkorn University
A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cell with IL-7Ra signal targeting B7H3 in children with diffuse intrinsic pontine glioma (DIPG) patients after complete standard treatments.
This description comes directly from the study's public registry record.
Piti Techavichit, MD · 6622564900 · piti.t@chula.ac.th
Koramit Suppipat, MD · 6622564900 · koramit.s@chula.ac.th
Always discuss trial participation with your own doctor first.
| King Chulalongkorn Memorial Hospital | Bangkok, Pathumwan, Thailand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06221553